{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:20:12Z","timestamp":1792200012993,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Ambulatory patients presenting with signs or symptoms of heart failure (HF) should undergo natriuretic peptide testing. Rates of death, HF hospitalization, and healthcare costs were examined in patients thus identified with suspected de novo HF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This population-based study (REVOLUTION HF) encompassing two large healthcare regions in Sweden examined patients who presented to outpatient care for the first time between 1 January 2015 and 31 December 2020, who had a recorded sign (peripheral oedema) or symptom (dyspnoea) of HF, and whose N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured &amp;gt;300\u2005ng\/L within \u00b130 days of that sign or symptom. Characteristics, outcomes, healthcare patterns, and healthcare costs for these patients were followed for 1 year. Comparisons were made with matched controls without history of HF, its signs, its symptoms, or elevated NT-proBNP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 5942 patients (median age 78.7 years; 54% women) presented with suspected de novo HF. Within 1 year, 29% had received a HF diagnosis. Patients with suspected de novo HF had higher rates of all-cause death (11.7 vs. 6.5 events\/100 person-years) and HF hospitalizations (12.5 vs. 2.2 events\/100 person-years) than matched controls (n = 2048), with the highest event rates in the weeks after presentation. Rates were higher with higher NT-proBNP levels. Although some patients already used HF guideline-directed medical therapies for other indications, initiation of new medications was variable. Healthcare costs were higher in patients with suspected de novo HF than in matched controls, driven mostly by HF and chronic kidney disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs, highlighting an urgent need for prompt identification, evaluation, and treatment of HF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf034","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:33:24Z","timestamp":1738269204000},"page":"1493-1503","source":"Crossref","is-referenced-by-count":22,"title":["Suspected <i>de novo<\/i> heart failure in outpatient care: the REVOLUTION HF study"],"prefix":"10.1093","volume":"46","author":[{"given":"Lisa","family":"Anderson","sequence":"first","affiliation":[{"name":"Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George\u2019s, University of London and St George\u2019s University Hospitals NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-197X","authenticated-orcid":false,"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"Heart Institute, Hospital Universitari German Trias i Pujol, Universitat Autonoma de Barcelona, CIBERCV , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3967","authenticated-orcid":false,"given":"Johan","family":"Bodeg\u00e5rd","sequence":"additional","affiliation":[{"name":"Cardiovascular Renal and Metabolism Evidence, BioPharmaceuticals Medical, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Mullin","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Sence Research , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-2263","authenticated-orcid":false,"given":"Giuseppe M C","family":"Rosano","sequence":"additional","affiliation":[{"name":"Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George\u2019s, University of London and St George\u2019s University Hospitals NHS Foundation Trust , London ,","place":["UK"]},{"name":"Cardiology, San Raffaele Hospital Cassino , Cassino ,","place":["Italy"]},{"name":"Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"The George Institute for Global Health, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2025042122370910400_ehaf034-B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2025042122370910400_ehaf034-B2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/heartjnl-2022-321702","article-title":"Prevalence, outcomes and costs of a contemporary, multinational population with heart failure","volume":"109","author":"Norhammar","year":"2023","journal-title":"Heart"},{"key":"2025042122370910400_ehaf034-B3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the heart failure association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025042122370910400_ehaf034-B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1411430","article-title":"The public\u2013private pendulum \u2013 patient choice and equity in Sweden","volume":"372","author":"Anell","year":"2015","journal-title":"N Engl J Med"},{"key":"2025042122370910400_ehaf034-B5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2025042122370910400_ehaf034-B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14017431.2020.1820075","article-title":"Reorganization of heart failure management and improved outcome \u2013 the 4D HF project","volume":"55","author":"Matan","year":"2021","journal-title":"Scand Cardiovasc J"},{"key":"2025042122370910400_ehaf034-B7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ehf2.14685","article-title":"Heart failure outcomes by left ventricular ejection fraction in a contemporary region-wide patient cohort","volume":"11","author":"Sundstrom","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2025042122370910400_ehaf034-B8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/heartjnl-2017-312183","article-title":"Routes to diagnosis of heart failure: observational study using linked data in England","volume":"104","author":"Bottle","year":"2018","journal-title":"Heart"},{"key":"2025042122370910400_ehaf034-B9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ejhf.110","article-title":"Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion","volume":"16","author":"van Riet","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2025042122370910400_ehaf034-B10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/ejhf.709","article-title":"Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people","volume":"19","author":"Koudstaal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025042122370910400_ehaf034-B11","doi-asserted-by":"publisher","first-page":"e1002805","DOI":"10.1371\/journal.pmed.1002805","article-title":"Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients","volume":"16","author":"Conrad","year":"2019","journal-title":"PLoS Med"},{"key":"2025042122370910400_ehaf034-B12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/eurjhf\/hfq185","article-title":"Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?","volume":"13","author":"Ezekowitz","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2025042122370910400_ehaf034-B13","author":"National Institute for Health and Care Excellence"},{"key":"2025042122370910400_ehaf034-B14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3892\/ol.2023.13866","article-title":"Levels of NT-proBNP in patients with cancer","volume":"26","author":"Chovanec","year":"2023","journal-title":"Oncol Lett"},{"key":"2025042122370910400_ehaf034-B15","doi-asserted-by":"publisher","first-page":"e032257","DOI":"10.1161\/JAHA.123.032257","article-title":"Usefulness of heart failure categories based on left ventricular ejection fraction","volume":"13","author":"Christersson","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025042122370910400_ehaf034-B16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2025042122370910400_ehaf034-B17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the non-steroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2024","journal-title":"Circulation"},{"key":"2025042122370910400_ehaf034-B18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jchf.2023.04.017","article-title":"Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/16\/1493\/61853031\/ehaf034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/16\/1493\/61853031\/ehaf034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T02:37:16Z","timestamp":1745289436000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/16\/1493\/8009274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":18,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,2,12]]},"published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf034","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,21]]},"published":{"date-parts":[[2025,2,12]]}}}